PBPIA
ETTX

Pivotal bioVenture Partners Investment Advisor’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio ETTX Stock Details ETTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,176,378
Closed -$2.52M – 9
2021
Q1 		$2.52M Sell
1,176,378
-3,800
-0.3% -$10.8K 0.81% 9
2020
Q4 		$2.92M Buy
+1,180,178
New +$2.32M 0.96% 8

Other funds holding ETTX

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's ETTX Position: Q2 2021 in Review

Pivotal bioVenture Partners Investment Advisor sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q2 2021, closing a stake of 1,176,378 shares — an estimated $2.52M sold.

Pivotal bioVenture Partners Investment Advisor first reported a position in ETTX in Q4 2020 and held it in 2 quarters. The position peaked at $2.92M in Q4 2020. 24 funds tracked by Wall St. Rank hold ETTX as of Q2 2021.

  • Pivotal bioVenture Partners Investment Advisor reported no remaining Entasis Therapeutics Holdings Inc. position as of Q2 2021 after selling out during the quarter.
  • Pivotal bioVenture Partners Investment Advisor sold 1,176,378 Entasis Therapeutics Holdings Inc. shares in Q2 2021, an estimated $2.52M.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Entasis Therapeutics Holdings Inc. in Q4 2020 and held it in 2 quarters.
  • Pivotal bioVenture Partners Investment Advisor's Entasis Therapeutics Holdings Inc. position peaked at $2.92M in Q4 2020.
  • 24 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q2 2021.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2021, filed 16 Aug 2021.